Workflow
金城医药(300233.SZ):子公司“普罗雌烯乳膏”获得韩国药品进口许可
Jincheng PharmJincheng Pharm(SZ:300233) 智通财经网·2025-07-31 09:49

Core Viewpoint - The company Jin Cheng Pharmaceutical has received an import license for Progestin Cream from the Korean Ministry of Food and Drug Safety, marking a significant step in expanding its product offerings in the treatment of Genitourinary Syndrome of Menopause (GSM) [1] Company Summary - Jin Cheng Pharmaceutical's wholly-owned subsidiary, Beijing Jin Cheng Tai Er Pharmaceutical Co., Ltd., has obtained the import license for Progestin Cream [1] - Progestin is currently the only marketed estrogen with strict local action, used for treating atrophic changes in the vulva, vestibule, and vaginal ring, as well as associated symptoms such as discomfort, itching, burning, and dryness [1] Industry Summary - The conditions treated by Progestin Cream are caused by decreased levels of estrogen and other sex hormones in women during the perimenopausal and postmenopausal periods, collectively referred to as Genitourinary Syndrome of Menopause (GSM) [1] - Guidelines both domestically and internationally recommend local estrogen use as the first-line treatment for GSM, with Progestin Cream being one of the options [1] - According to IMS data, global sales of Progestin formulations are projected to be $78.10 million in 2022, $94.34 million in 2023, and $103.86 million in 2024 [1]